Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: NOPHO Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults(18.0-45.0 Years) With Acute Lymphoblastic Leukemia. Intermittent Versus Continuous PEG-asparaginase for Asparagine Depletion
Brief Summary: The purpose of this study is to investigate if intramuscular PEG-asparaginase administered either at six or two week intervals from day 92 until 8 months from diagnosis for patients with non-HR ALL will result in equal probability of Event Free Survival


Options:
A: Arm Label: SC-PEG (Arm A); Type: ACTIVE_COMPARATOR; Interventions: Drug: SC-PEG | Arm Label: Oncaspar (Arm B); Type: ACTIVE_COMPARATOR; Interventions: Drug: Oncaspar | Intervention Type: DRUG; Name: SC-PEG; Assigned to Arm(s): SC-PEG (Arm A) | Intervention Type: DRUG; Name: Oncaspar; Assigned to Arm(s): Oncaspar (Arm B)
B: Arm Label: Stratum I (radiotherapy, chemoprotective agent); Type: EXPERIMENTAL; Interventions: Drug: Amifostine, Other: Laboratory Biomarker Analysis, Radiation: Radiation Therapy | Arm Label: Stratum II (chemotherapy, chemoprotective agent, radiotherapy); Type: EXPERIMENTAL; Interventions: Drug: Amifostine, Drug: Cisplatin, Drug: Fluorouracil, Other: Laboratory Biomarker Analysis, Radiation: Radiation Therapy | Intervention Type: DRUG; Name: Amifostine; Assigned to Arm(s): Stratum I (radiotherapy, chemoprotective agent), Stratum II (chemotherapy, chemoprotective agent, radiotherapy) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Stratum II (chemotherapy, chemoprotective agent, radiotherapy) | Intervention Type: DRUG; Name: Fluorouracil; Assigned to Arm(s): Stratum II (chemotherapy, chemoprotective agent, radiotherapy) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Stratum I (radiotherapy, chemoprotective agent), Stratum II (chemotherapy, chemoprotective agent, radiotherapy) | Intervention Type: RADIATION; Name: Radiation Therapy; Assigned to Arm(s): Stratum I (radiotherapy, chemoprotective agent), Stratum II (chemotherapy, chemoprotective agent, radiotherapy)
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Drug: asparaginase, Drug: cyclophosphamide, Drug: cytarabine, Drug: daunorubicin, Drug: mercaptopurine, Drug: Methotrexate, Drug: prednisone, Drug: Vincristine | Arm Label: II; Type: EXPERIMENTAL; Interventions: Drug: dexamethasone, Drug: asparaginase, Drug: cyclophosphamide, Drug: cytarabine, Drug: daunorubicin, Drug: mercaptopurine, Drug: Methotrexate, Drug: Vincristine | Arm Label: Reintensification Arm I; Type: EXPERIMENTAL; Interventions: Drug: Asparaginase, Drug: cyclophosphamide, Drug: cytarabine, Drug: doxorubicin, Drug: mercaptopurine, Drug: Methotrexate, Drug: thioguanine, Drug: Vincristine | Arm Label: Reintensification Arm II; Type: EXPERIMENTAL; Interventions: Drug: Asparaginase, Drug: cyclophosphamide, Drug: cytarabine, Drug: doxorubicin, Drug: mercaptopurine, Drug: Methotrexate, Drug: thioguanine, Drug: Vincristine | Arm Label: Reintensification Arm III; Type: EXPERIMENTAL; Interventions: Drug: Asparaginase, Drug: cytarabine, Drug: doxorubicin, Drug: mercaptopurine, Drug: Methotrexate, Drug: Vincristine | Arm Label: Reintensification Arm IV; Type: EXPERIMENTAL; Interventions: Drug: Etoposide, Drug: Ifosfamide, Drug: Methotrexate, Drug: Vincristine, Drug: Vindesine | Arm Label: Reintensification Arm V; Type: EXPERIMENTAL; Interventions: Drug: Etoposide, Drug: Ifosfamide, Drug: Methotrexate, Drug: Vincristine, Drug: Vindesine | Intervention Type: DRUG; Name: dexamethasone; Assigned to Arm(s): II | Intervention Type: DRUG; Name: asparaginase; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: Asparaginase; Assigned to Arm(s): Reintensification Arm I, Reintensification Arm II, Reintensification Arm III | Intervention Type: DRUG; Name: cyclophosphamide; Assigned to Arm(s): I, II, Reintensification Arm I, Reintensification Arm II | Intervention Type: DRUG; Name: cytarabine; Assigned to Arm(s): I, II, Reintensification Arm I, Reintensification Arm II, Reintensification Arm III | Intervention Type: DRUG; Name: daunorubicin; Assigned to Arm(s): I, II | Intervention Type: DRUG; Name: doxorubicin; Assigned to Arm(s): Reintensification Arm I, Reintensification Arm II, Reintensification Arm III | Intervention Type: DRUG; Name: Etoposide; Assigned to Arm(s): Reintensification Arm IV, Reintensification Arm V | Intervention Type: DRUG; Name: Ifosfamide; Assigned to Arm(s): Reintensification Arm IV, Reintensification Arm V | Intervention Type: DRUG; Name: mercaptopurine; Assigned to Arm(s): I, II, Reintensification Arm I, Reintensification Arm II, Reintensification Arm III | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): I, II, Reintensification Arm I, Reintensification Arm II, Reintensification Arm III, Reintensification Arm IV, Reintensification Arm V | Intervention Type: DRUG; Name: prednisone; Assigned to Arm(s): I | Intervention Type: DRUG; Name: thioguanine; Assigned to Arm(s): Reintensification Arm I, Reintensification Arm II | Intervention Type: DRUG; Name: Vincristine; Assigned to Arm(s): I, II, Reintensification Arm I, Reintensification Arm II, Reintensification Arm III, Reintensification Arm IV, Reintensification Arm V | Intervention Type: DRUG; Name: Vindesine; Assigned to Arm(s): Reintensification Arm IV, Reintensification Arm V
D: Arm Label: PEG-asparaginase 6 weeks intervals; Type: EXPERIMENTAL; Interventions: Drug: PEG Asparaginase at six weeks interval | Arm Label: PEG-Asparaginase 2 weeks intervals; Type: ACTIVE_COMPARATOR; Interventions: Drug: PEG Asparaginase at two weeks interval | Intervention Type: DRUG; Name: PEG Asparaginase at six weeks interval; Assigned to Arm(s): PEG-asparaginase 6 weeks intervals | Intervention Type: DRUG; Name: PEG Asparaginase at two weeks interval; Assigned to Arm(s): PEG-Asparaginase 2 weeks intervals

Answer: D